secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2026-06-02T12:10:25+00:00
Accession:  0001493152-26-026760
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate receives FDA Complete Response Letter for CTx-1301; no safety/efficacy issues, CMC-only
--------------------------------------------------------------------------------

- FDA issued a Complete Response Letter for CTx-1301 (dexmethylphenidate HCl) NDA for ADHD.
- No current concerns about clinical safety or efficacy; CMC information requests identified.
- Company expects prompt resubmission of requested CMC data; has ~$30M cash on hand.
- NDA previously accepted with PDUFA target date of May 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/0001493152-26-026760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-026760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer